The Resolution of Inflammation Through Omega-3 Fatty Acids in Atherosclerosis, Intimal Hyperplasia, and Vascular Calcification

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2019 Nov 8

PMID 31696250

Citations 44

Authors

Miguel Carracedo

Gonzalo Artiach

Hildur Arnardottir

Magnus Back

Affiliations

Soon will be listed here.

Abstract

Omega-3 fatty acids serve as the substrate for the formation of a group of lipid mediators that mediate the resolution of inflammation. The cardiovascular inflammatory response in atherosclerosis and vascular injury is characterized by a failure in the resolution of inflammation, resulting in a chronic inflammatory response. The proresolving lipid mediator resolvin E1 (RvE1) is formed by enzymatic conversion of the omega-3 fatty acid eicosapentaenoic acid (EPA), and signals resolution of inflammation through its receptor ChemR23. Importantly, the resolution of cardiovascular inflammation is an active, multifactorial process that involves modulation of the immune response, direct actions on the vascular wall, as well as close interactions between macrophages and vascular smooth muscle cells. Promoting anti-atherogenic signalling through the stimulation of endogenous resolution of inflammation pathways may provide a novel therapeutic strategy in cardiovascular prevention.

Citing Articles

Amentoflavone for treating cardiocerebrovascular diseases and neurological disorders.

Zhang H, Ban Y, Li D, Wang G, Gu J, Zhu L Front Pharmacol. 2024; 15:1406510.

PMID: 39624841 PMC: 11608994. DOI: 10.3389/fphar.2024.1406510.

Proresolving Lipid Mediators in the Respiratory System.

Serhan C, Levy B Annu Rev Physiol. 2024; 87(1):491-512.

PMID: 39303274 PMC: 11810588. DOI: 10.1146/annurev-physiol-020924-033209.

Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies.

Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, Weylandt K Nutrients. 2024; 16(11).

PMID: 38892543 PMC: 11174367. DOI: 10.3390/nu16111610.

Role of long-chain polyunsaturated fatty acids, eicosapentaenoic and docosahexaenoic, in the regulation of gene expression during the development of obesity: a systematic review.

Sandoval C, Nahuelqueo K, Mella L, Recabarren B, Souza-Mello V, Farias J Front Nutr. 2023; 10:1288804.

PMID: 38024342 PMC: 10665854. DOI: 10.3389/fnut.2023.1288804.

Oxylipin secretion by human CD3 T lymphocytes is modified by the exogenous essential fatty acid ratio and life stage.

von Gerichten J, West A, Irvine N, Miles E, Calder P, Lillycrop K Front Immunol. 2023; 14:1206733.

PMID: 37388745 PMC: 10300345. DOI: 10.3389/fimmu.2023.1206733.

References

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

Sekikawa A, Miura K, Lee S, Fujiyoshi A, Edmundowicz D, Kadowaki T . Long chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese men in Japan and white men in the USA: population based prospective cohort study. Heart. 2013; 100(7):569-73. PMC: 3949146. DOI: 10.1136/heartjnl-2013-304421. View

Allahverdian S, Chaabane C, Boukais K, Francis G, Bochaton-Piallat M . Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res. 2018; 114(4):540-550. PMC: 5852505. DOI: 10.1093/cvr/cvy022. View

Hiram R, Rizcallah E, Marouan S, Sirois C, Sirois M, Morin C . Resolvin E1 normalizes contractility, Ca2+ sensitivity and smooth muscle cell migration rate in TNF-α- and IL-6-pretreated human pulmonary arteries. Am J Physiol Lung Cell Mol Physiol. 2015; 309(8):L776-88. DOI: 10.1152/ajplung.00177.2015. View

Ho K, Spite M, Owens C, Lancero H, Kroemer A, Pande R . Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010; 177(4):2116-23. PMC: 2947304. DOI: 10.2353/ajpath.2010.091082. View

Van Noolen L, Back M, Arnaud C, Rey A, Petri M, Levy P . Docosahexaenoic acid supplementation modifies fatty acid incorporation in tissues and prevents hypoxia induced-atherosclerosis progression in apolipoprotein-E deficient mice. Prostaglandins Leukot Essent Fatty Acids. 2014; 91(4):111-7. DOI: 10.1016/j.plefa.2014.07.016. View

Fredman G, Tabas I . Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol. 2017; 187(6):1211-1221. PMC: 5455064. DOI: 10.1016/j.ajpath.2017.01.018. View

Back M, Hansson G . Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015; 12(4):199-211. DOI: 10.1038/nrcardio.2015.5. View

Back M . Inflammatory signaling through leukotriene receptors in atherosclerosis. Curr Atheroscler Rep. 2008; 10(3):244-51. DOI: 10.1007/s11883-008-0038-7. View

10.

Makino Y, Miyahara T, Nitta J, Miyahara K, Seo A, Kimura M . Proresolving Lipid Mediators Resolvin D1 and Protectin D1 Isomer Attenuate Neointimal Hyperplasia in the Rat Carotid Artery Balloon Injury Model. J Surg Res. 2018; 233:104-110. DOI: 10.1016/j.jss.2018.07.049. View

11.

van der Vorst E, Mandl M, Muller M, Neideck C, Jansen Y, Hristov M . Hematopoietic ChemR23 (Chemerin Receptor 23) Fuels Atherosclerosis by Sustaining an M1 Macrophage-Phenotype and Guidance of Plasmacytoid Dendritic Cells to Murine Lesions-Brief Report. Arterioscler Thromb Vasc Biol. 2019; 39(4):685-693. DOI: 10.1161/ATVBAHA.119.312386. View

12.

Pope N, Salmon M, Davis J, Chatterjee A, Su G, Conte M . D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization. FASEB J. 2016; 30(12):4192-4201. PMC: 5102115. DOI: 10.1096/fj.201600144RR. View

13.

Sekikawa A, Mahajan H, Kadowaki S, Hisamatsu T, Miyagawa N, Fujiyoshi A . Association of blood levels of marine omega-3 fatty acids with coronary calcification and calcium density in Japanese men. Eur J Clin Nutr. 2018; 73(5):783-792. PMC: 6348058. DOI: 10.1038/s41430-018-0242-7. View

14.

Pirault J, Back M . Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease. Front Pharmacol. 2018; 9:1273. PMC: 6247824. DOI: 10.3389/fphar.2018.01273. View

15.

Kanai S, Uto K, Honda K, Hagiwara N, Oda H . Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats. Atherosclerosis. 2011; 215(1):43-51. DOI: 10.1016/j.atherosclerosis.2010.12.001. View

16.

Tunon J, Badimon L, Bochaton-Piallat M, Cariou B, Daemen M, Egido J . Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res. 2018; 115(1):10-19. PMC: 6302260. DOI: 10.1093/cvr/cvy293. View

17.

Shah P . Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation. 2003; 107(17):2175-7. DOI: 10.1161/01.CIR.0000069943.41206.BD. View

18.

Stanke-Labesque F, Pepin J, Gautier-Veyret E, Levy P, Back M . Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovasc Res. 2013; 101(2):187-93. DOI: 10.1093/cvr/cvt247. View

19.

Sima C, Montero E, Nguyen D, Freire M, Norris P, Serhan C . ERV1 Overexpression in Myeloid Cells Protects against High Fat Diet Induced Obesity and Glucose Intolerance. Sci Rep. 2017; 7(1):12848. PMC: 5634420. DOI: 10.1038/s41598-017-13185-7. View

20.

Conte M, Desai T, Wu B, Schaller M, Werlin E . Pro-resolving lipid mediators in vascular disease. J Clin Invest. 2018; 128(9):3727-3735. PMC: 6118638. DOI: 10.1172/JCI97947. View